Gilead Sciences, Inc.

Profile narrative

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutic agents for the treatment of serious medical conditions. Its core portfolio centers on antiviral medicines, including products for HIV infection, hepatitis B and C, and influenza, as well as oncology therapies targeting hematologic malignancies and solid tumors. The company also engages in research on emerging infectious diseases, most notably producing the antiviral remdesivir that received emergency use authorization during the COVID‑19 pandemic. Gilead’s scientific efforts are supported by a robust pipeline of small‑molecule and biologic candidates that aim to address unmet medical needs across multiple therapeutic areas. Its medicines are distributed through a global commercial network that serves healthcare providers and patients in North America, Europe, Asia, and other regions.

The organization distinguishes itself through a longstanding specialization in antiviral research, a field in which it has achieved regulatory approvals for several first‑in‑class and best‑in‑class therapies. This focus has positioned Gilead as a leader in the HIV treatment market, where its combination regimens have become standards of care. In addition to virology, the company has built notable competencies in oncology, leveraging its expertise in targeted drug design to bring forward therapies for lymphoma and lung cancer. Structurally, Gilead Sciences, Inc. remains an independent, publicly traded corporation listed on the NASDAQ under the ticker GILD, with no parent company or major subsidiary relationships disclosed in the available sources. The 2020 phishing campaign attributed to Iranian threat actors, which attempted to compromise employee email accounts amid the company’s COVID‑19 therapeutic work, illustrates the heightened cyber‑risk environment faced by firms engaged in pandemic‑related research.

Incidents

1 incident linked to this organisation.